June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
“Uncomplicated” Urinary Tract Infections: Remember When They Were Easy?
March 18th 2024In the latest issue, Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the continuous antibiotic trade-off of targeted vs broad spectrum therapies and cheap vs expensive options as they relate to UTI treatment.
Read More
All About the JUICE: Justifying Use of Non-Carbapenems for Infected NeCrotizing PancrEatitis
March 7th 2024Management of this condition has been associated with antibiotic misuse. In the latest Bench to Bedside column, clinicians offer insights on therapy indications and what the latest literature reports on the condition.
Read More
FDA Issues a CRL for Venatorx Pharmaceuticals’ Antibiotic for Treatment of Complicated UTI
February 23rd 2024The federal agency did not request further trials for the investigational therapy, cefepime-taniborbactam, but wanted more information about its chemistry, manufacturing, and controls.
Read More
Investigational Antibiotic Outperforms Meropenem in Treating Complicated UTI
February 16th 2024A recently published study demonstrated the superior efficacy of cefepime–taniborbactam over meropenem for managing complicated urinary tract infections, suggesting a promising treatment option amid rising antibiotic resistance challenges.
Read More
Antibiotic De-Escalation: Is This the Right Outcome Measure?
November 16th 2023The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
Read More
Two Pragmatic Approaches to Skin and Soft Tissue Infections
November 14th 2023Empirical antibiotic therapy in diabetic foot ulcer infections increases hospitalization and prolonged symptoms in patients being treated for lower limb cellulitis are common. Two recent papers examine the need for effective communication, the importance of objective findings in cellulitis management, and the benefits of culture-based antibiotic therapy in diabetic foot ulcer cases.
Read More